A new class of lung cancer drugs is offering real hope to patients whose tumors carry rare genetic mutations that were, until recently, considered nearly untreatable. In early 2026, the FDA granted breakthrough therapy designation to zoldonrasib, an investigational drug developed by Revolution Medicines that targets the notoriously difficult KRAS G12D mutation in non-small cell lung cancer. Among 18 patients in clinical trials who had been on the drug for at least eight weeks, 61 percent experienced substantial tumor shrinkage, and 89 percent achieved disease control. For families affected by dementia who are also navigating a loved one’s cancer diagnosis, or for older adults managing multiple serious conditions, these advances represent a meaningful shift in what is possible.
Zoldonrasib is not the only new treatment making headlines. The FDA also granted accelerated approval to zongertinib, marketed as Hernexeos, for patients with HER2-mutated lung cancer, and Eli Lilly reported a significant win for Retevmo in early-stage RET fusion-positive lung cancer. Each of these drugs targets a different rare mutation, and together they signal a broader trend: oncology is moving toward highly personalized treatments that match specific drugs to specific genetic drivers of cancer. This article covers what these rare mutations are and why they have been so hard to treat, how each of these new drugs works, what the clinical trial results actually show, and what caregivers and patients should know about accessing these therapies. For readers on a dementia care and brain health site, we also address the particular challenges of managing a cancer diagnosis alongside cognitive decline.
Table of Contents
- What Are the Rare Lung Cancer Mutations These New Drugs Target?
- How Does Zoldonrasib Work Against the KRAS G12D Mutation?
- Zongertinib Becomes the First Approved First-Line HER2 Therapy for Lung Cancer
- What Should Patients and Caregivers Know About Accessing These Treatments?
- The Challenge of Managing Cancer Treatment Alongside Cognitive Decline
- Retevmo’s Adjuvant Trial Signals a Shift Toward Treating Rare Cancers Earlier
- What the Future Holds for Rare Mutation Lung Cancer Treatment
- Conclusion
- Frequently Asked Questions
What Are the Rare Lung Cancer Mutations These New Drugs Target?
Not all lung cancers are the same. At the molecular level, tumors are driven by specific genetic mutations, and identifying the exact mutation in a patient’s cancer is now central to choosing the right treatment. The KRAS G12D mutation, which zoldonrasib targets, is found in a subset of non-small cell lung cancers and has long been considered one of the hardest mutations to drug. For years, researchers called KRAS proteins “undruggable” because their smooth, round shape offered few places for a drug molecule to latch on. The breakthrough therapy designation for zoldonrasib, granted in January 2026, marks the first time any investigational drug has received this status for KRAS G12D in lung cancer. HER2 mutations present a different challenge. They occur in roughly 2 percent of non-small cell lung cancers, making them genuinely rare.
Until zongertinib’s approval in February 2026, patients with HER2-mutated lung cancer had no targeted first-line therapy designed specifically for their tumor type. They were often treated with drugs approved for other cancer types or enrolled in clinical trials. RET fusions, the target of Retevmo, are another uncommon biomarker found in both lung and thyroid cancers. The common thread is that all of these mutations affect small patient populations, which historically meant less commercial incentive to develop drugs for them and fewer treatment options. Compared to more common mutations like EGFR, which has had targeted therapies available for over a decade, these rare subtypes have left patients with fewer choices and often worse outcomes. The recent wave of approvals and designations is closing that gap, though it remains important to understand that not every patient with lung cancer carries one of these mutations. Comprehensive genomic testing is the only way to know.
How Does Zoldonrasib Work Against the KRAS G12D Mutation?
Zoldonrasib, developed by Revolution Medicines, works by directly inhibiting the KRAS G12D protein, which acts as a faulty switch that tells cancer cells to grow and divide uncontrollably. The drug was studied in patients with locally advanced or metastatic NSCLC whose disease had already progressed after treatment with both anti-PD-1 or PD-L1 immunotherapy and platinum-based chemotherapy. In other words, these were patients who had already exhausted standard treatment options. The clinical trial results were striking: among 18 evaluable patients who had been on the drug for at least eight weeks, 61 percent saw their tumors shrink substantially, and 89 percent achieved disease control, meaning their cancer either shrank or at least stopped growing. However, it is important to note that these results come from a relatively small group of patients, and the drug has not yet received full FDA approval.
Breakthrough therapy designation speeds up the review process and signals that early evidence shows a meaningful advantage over existing treatments, but it does not guarantee approval. Patients and caregivers should understand that zoldonrasib is still investigational, and longer-term data on durability of response and overall survival are still being collected. If a loved one with dementia is also managing a KRAS G12D lung cancer diagnosis, the decision to pursue a clinical trial requires careful consideration of the cognitive and physical demands of treatment, including frequent hospital visits and monitoring. The drug also specifically targets the G12D variant of the KRAS mutation. Other KRAS variants, such as G12C, already have approved targeted therapies like sotorasib and adagrasib. Patients whose tumors carry a different KRAS mutation would not be candidates for zoldonrasib, which underscores why precise molecular testing matters.
Zongertinib Becomes the First Approved First-Line HER2 Therapy for Lung Cancer
On February 26, 2026, the FDA granted accelerated approval to zongertinib, sold under the brand name Hernexeos, for adults with unresectable or metastatic non-squamous NSCLC with HER2 tyrosine kinase domain activating mutations. Developed by Boehringer Ingelheim, this drug is notable for being the first HER2-targeting therapy approved as an initial treatment for this patient population. Previously, patients with HER2-mutated lung cancer might have received trastuzumab deruxtecan, which was approved in a later-line setting, or been treated with chemotherapy regimens not specifically designed for their mutation. The approval came under the FDA’s National Priority Voucher Pilot Program, making it only the second drug approved through this pathway.
This program is designed to incentivize the development of treatments for serious conditions by rewarding companies with a voucher that can expedite the review of a future drug. For patients, the practical result is faster access to a drug that was specifically tested and approved for their rare cancer subtype. For caregivers managing a loved one with both cognitive decline and a new cancer diagnosis, zongertinib’s oral formulation is a practical consideration. Oral drugs can sometimes be easier to manage in a home setting than intravenous infusions, though adherence to a daily medication regimen may require caregiver support, particularly if the patient has moderate to advanced dementia.
What Should Patients and Caregivers Know About Accessing These Treatments?
The first and most critical step is comprehensive biomarker testing. Without it, neither the patient nor the oncologist will know whether a rare mutation is driving the cancer. Guidelines from the National Comprehensive Cancer Network recommend broad molecular profiling for all patients with advanced non-small cell lung cancer, but in practice, not every patient receives it. Older adults, particularly those with cognitive impairment, may fall through the cracks if their care is fragmented across multiple providers. Caregivers should specifically ask the oncology team whether next-generation sequencing or equivalent testing has been ordered.
There is a tradeoff between pursuing cutting-edge targeted therapy and managing quality of life, especially for patients with co-existing dementia. Clinical trials for drugs like zoldonrasib require regular scans, blood work, and clinic visits. For a patient with significant cognitive decline, the burden of frequent travel and medical procedures can be substantial and may outweigh the potential benefit, particularly if the cancer is slow-growing. Conversely, for a patient whose dementia is mild and whose cancer is aggressive, a targeted therapy with a high response rate could meaningfully extend life. These are deeply personal decisions that deserve honest conversations with both the oncology and neurology teams. Patients who are not eligible for clinical trials or newly approved drugs should also know about expanded access programs, sometimes called compassionate use, which allow patients to receive investigational drugs outside of a trial in certain circumstances.
The Challenge of Managing Cancer Treatment Alongside Cognitive Decline
One of the less discussed realities of these advances is that many lung cancer patients are older adults, and a significant number also live with some degree of cognitive impairment. Dementia does not disqualify someone from cancer treatment, but it complicates nearly every aspect of care. Informed consent, medication adherence, recognizing and reporting side effects, and making decisions about continuing or stopping treatment all become more difficult when cognition is compromised. Drug interactions are another concern. Many targeted cancer therapies are metabolized through liver enzymes that can interact with medications commonly used in dementia care, including cholinesterase inhibitors like donepezil and memantine.
While no specific interaction warnings have been issued for zoldonrasib or zongertinib with these drugs, oncologists and neurologists do not always coordinate closely enough to catch potential problems. Caregivers should ensure that every prescribing physician has a complete medication list and should not hesitate to ask a pharmacist to run an interaction check. There is also the emotional toll. A caregiver already managing a loved one’s dementia may feel overwhelmed by the complexity of a cancer treatment plan. Support from palliative care teams, which focus on quality of life and symptom management regardless of treatment intent, can be invaluable in these situations and should not be reserved only for end-of-life care.
Retevmo’s Adjuvant Trial Signals a Shift Toward Treating Rare Cancers Earlier
Eli Lilly reported in February 2026 that Retevmo, the brand name for selpercatinib, achieved a highly statistically significant and clinically meaningful improvement in event-free survival in a Phase 3 trial of patients with early-stage RET fusion-positive NSCLC. This is significant because most targeted therapies for rare mutations have been studied and approved in the advanced or metastatic setting, meaning patients whose cancer has already spread.
The Retevmo trial studied adjuvant therapy, which means treatment given after surgery to reduce the risk of the cancer coming back. If this data leads to a new approval, it would mean that patients with RET fusions caught at stage II or IIIA could receive a targeted drug designed for their specific mutation before their cancer has a chance to recur. For older adults and their caregivers, early-stage treatment is generally less burdensome than managing metastatic disease, which could be particularly meaningful when dementia is also in the picture.
What the Future Holds for Rare Mutation Lung Cancer Treatment
The broader trend is unmistakable. Lung cancer treatment is becoming increasingly personalized, with therapies matched to the specific molecular profile of each patient’s tumor. Sevabertinib, also known as Hyrnuo, has received breakthrough therapy designation for first-line treatment of HER2-mutant NSCLC, adding yet another option to a space that had almost none just a few years ago. Researchers are also investigating combinations of targeted therapies with immunotherapy, which could further improve outcomes for patients with rare mutations.
For the dementia care community, these developments matter because the population most affected by both conditions overlaps significantly. Lung cancer incidence rises with age, as does dementia prevalence. As targeted therapies become more effective and potentially less toxic than traditional chemotherapy, they may become more feasible options for older adults managing multiple serious health conditions. The key is ensuring that patients with cognitive impairment are not excluded from these advances by default, and that caregivers are empowered with enough information to advocate for appropriate testing and treatment.
Conclusion
The landscape of treatment for rare-mutation lung cancer is changing rapidly. Zoldonrasib’s breakthrough designation for KRAS G12D, zongertinib’s accelerated approval for HER2-mutated NSCLC, Retevmo’s adjuvant trial success in RET fusion-positive disease, and sevabertinib’s breakthrough designation for HER2 mutations collectively represent a turning point.
Patients who once had few or no targeted options now have drugs specifically designed for their tumors, with clinical data showing meaningful response rates. For caregivers and families navigating the intersection of dementia and cancer, the most important takeaway is to insist on comprehensive biomarker testing, coordinate closely between oncology and neurology teams, and have candid conversations about the benefits and burdens of treatment. These new drugs are powerful tools, but using them wisely requires understanding the whole patient, not just the tumor.
Frequently Asked Questions
What is the KRAS G12D mutation, and why is it hard to treat?
KRAS G12D is a specific genetic mutation that drives some non-small cell lung cancers. The KRAS protein was long considered “undruggable” because its molecular structure offers few places for drugs to bind. Zoldonrasib is the first investigational drug to receive FDA breakthrough therapy designation for this mutation in lung cancer.
Is zongertinib (Hernexeos) available now?
Yes. The FDA granted accelerated approval to zongertinib on February 26, 2026, for adults with HER2-mutated non-squamous NSCLC. It is the first HER2-targeting therapy approved as a first-line treatment for this population.
Can a person with dementia receive targeted cancer therapy?
Dementia does not automatically disqualify someone from cancer treatment. However, it complicates informed consent, medication adherence, and side effect monitoring. The decision should involve both the oncology and neurology teams and should weigh the potential benefits against the treatment burden.
How do I know if my loved one’s lung cancer has a rare mutation?
Comprehensive biomarker testing, typically through next-generation sequencing, is the only way to determine if a lung cancer carries a targetable mutation. Guidelines recommend this testing for all patients with advanced NSCLC, but caregivers may need to specifically request it.
What is the difference between breakthrough therapy designation and FDA approval?
Breakthrough therapy designation is an FDA process that speeds up the development and review of a drug that shows substantial improvement over existing treatments in early clinical evidence. It does not mean the drug is approved. Full or accelerated approval comes after the FDA reviews more complete data on safety and efficacy.
Are there side effects specific to these new targeted therapies?
Each drug has its own side effect profile, and full safety data for investigational drugs like zoldonrasib are still being collected. Patients and caregivers should discuss potential side effects with the oncology team and ensure all prescribing physicians are aware of other medications the patient takes, particularly dementia drugs.
